Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Initiates Coverage On Fate Therapeutics with Sell Rating, Announces Price Target of $10

Goldman Sachs analyst Andrea Tan initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Sell rating and announces Price Target of $10.
byBenzinga Newsdesk
December 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Andrea Tan initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Sell rating and announces Price Target of $10.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts